Value-Based Medicine (VBM) for Lung Cancer
Validation of Predictive Model in Value-based Medicine for Lung Cancer and Analysis of Its Implications for Patient Communication
European Institute of Oncology
200 participants
Jan 27, 2021
OBSERVATIONAL
Conditions
Summary
This is a prospective observational monocentric trial. The primary endpoint is the validation of predictive models. These predictive models will be used to develop a personalized clinical-functional risk profile for estimating in advance, prior to surgery, the probability for a patient to experience surgical complications, pain, fatigue, dyspnea, as well as issues related to physical function, role, social, and emotional well-being, up to 12 months post-discharge.
Eligibility
Inclusion Criteria6
- Patients aged ≥ 18 years
- Patients with diagnosis of non-small cell lung carcinoma
- Only patients eligible for surgical lung resection (lobectomy/typical and atypical segmentectomy) with or without neo-adjuvant and adjuvant therapy
- Diagnosis of primary non-small cell lung cancer
- Signed Informed Consent
- Patients must be available for follow-up
Exclusion Criteria3
- Patients with benign lesion
- Patients with recurrence who have already undergone lung surgery
- Conditions/pathologies that prevent the ability to give consent
Interventions
Application of "value based medicine" predictive model
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06703866